Lansobene (Lansoprazole)

Lansoprazole selectively and irreversibly inhibits the H+/K+ ATPase enzyme, also known as the gastric proton pump, on the secretory surface of stomach parietal cells. This blockade stops the final step of acid secretion, leading to a sustained increase in gastric pH and allowing ulcerated or inflamed tissue to recover.

The appropriate dose of Lansobene is determined by the prescribing healthcare professional based on the specific indication, patient age, renal and hepatic function, and other clinical factors. Patients should follow the dosage instructions provided by their prescriber and not adjust the dose on their own.

Safety of Lansobene in pregnancy or lactation has not been fully established. The prescriber should evaluate the potential benefits against any possible risks to the fetus or infant. If treatment is necessary, it should be used only under medical supervision.

To request Lansobene, submit an enquiry on the product page at gnhindia.com specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, and will verify trade or institutional credentials before providing pricing, availability, shipping details and any required import documentation.

Lansobene (lansoprazole) belongs to the same class as omeprazole, esomeprazole and pantoprazole. All share a similar mechanism of irreversible proton pump inhibition, but differences exist in pharmacokinetic profiles, drug‑interaction potential and dosing frequency. Choice of agent often depends on physician preference, patient response and specific drug‑interaction considerations.

Lansobene should be stored at ambient temperature, below 25 °C, in its original packaging. Protect the tablets from moisture, excessive heat and direct sunlight to maintain product stability throughout its shelf life.

Lansobene is taken orally, usually as a whole tablet swallowed with a glass of water. It is generally recommended to take the medication before a meal, unless the prescriber provides alternative instructions based on the individual treatment plan.

Serious but rare adverse events linked to Lansobene include acute interstitial nephritis, severe allergic reactions such as anaphylaxis, and Clostridioides difficile‑associated diarrhoea. Patients should seek immediate medical attention if they experience symptoms like rash, swelling, breathing difficulty, or persistent watery stools.

Lansobene is contraindicated in patients with known hypersensitivity to lansoprazole or any component of the formulation. Caution is also advised for individuals with severe liver disease, those taking medications that require an acidic gastric environment for absorption, and patients with a history of allergic reactions to other proton pump inhibitors.